NEWS
G-BA resolutions on afamelanotide for the rare disease erythropoietic protoporphyria RAPS EURO Convergence Europe in Berlin on 7 May 2024
Obstacles for patient access to medicines can happen at different stages of a medicine's life cycle. Therefore, marketing authorisation should not be the ultimate goal. Patient, regulatory and HTA perspectives on an EU approved orphan drug were discussed at the RAPS...
Benefit assessment in Germany – G-BA resolutions on Zolgensma Market Access Day in Paris on 2 October 2023
The global community of market access professionals met in France on 2 October 2023 at the Market Access Day Paris 2023 – the first post-pandemic event of the Market Access Society (MAS). This meeting was also a great opportunity to discuss the latest developments of...
Spesolimab: Does the benefit assessment of medicines for rare diseases need more flexibility? The case of spesolimab (Spevigo®)
The G-BA Office in Berlin, GermanyAfter Boehringer Ingelheim’s announcement to withdraw a medicine for the treatment of a rare skin disease from the German market on 29 August 2023, a heated debate has erupted on the benefit assessment of new therapies in Germany....
AMNOG Gene Therapies in Oncology and Beyond Inaugural Meeting of IMAS on 3-5 April 2023 in Miami Beach, USA
Do you know IMAS? IMAS stands for International Market Access Society. As a matter of fact it derives from MAS, the Market Access Society founded in France more than 10 years ago. The very first meeting of IMAS called ACCESS 2023 Miami Beach took place in April 2023....
Rare Disease Day 2023 is a tricky day for orphan drugs Sharing colours sometimes takes time
I remember very well the day I asked the G-BA for permission to speak about the specific German benefit assessment of orphan drugs. Although I used to represent the G-BA and AMNOG internationally, I did not dare to give a talk solely on orphan drugs. Why? Because I...